Differentiated Clinical Pathway to realize Breakthrough Innovation in the Field of Heart and brain Imaging

36Kr Holdings learned that"Digital Science and Technology"Today announced the completion of a new round of financing of 590 million yuan. This round of financing is led by Sequoia Capital China Fund, followed by China re and CICC Pucheng, and veteran shareholders Huagai Capital, Wuyuan Capital, Chuangshi Partners CCV, QiMing Venture Partners and Yuanyi Capital. China Renaissance Capital Investment served as the exclusive financial adviser for this financing. Since the beginning of this year, the cumulative financing amount of "Jukun Science and Technology" has reached nearly 1 billion yuan.

This round of financing will be used to increase investment in the research and development of the original technology, continuously improve the product line of the core technology of "digital human body", and further speed up the landing and deployment of products in medical institutions at all levels. speed up the comprehensive coverage of digital medical productivity in the process of intelligent construction of hospitals across the country.

Since its establishment more than three years ago, "Digital Science and Technology" has made a breakthrough from "digital heart", and has built an intelligent platform for intelligent images of "digital human body", including "digital brain", "digital chest", "digital abdomen" and so on. It has realized the intelligence of the whole process of image diagnosis, and helped online hospitals to realize the medical service ability of "patients do as they come, reports are desirable". It has greatly improved the patient's medical experience and the efficiency of the use of medical resources in the hospital.

In November 2020, the heart AI of "Digital Science and Technology" was approved NMPA Class III Certificate, which became the first certificate in the field of cardiac stenosis AI, and also the first Class III Certificate in the Digital Heart product family. According to public data, the number of cardiovascular patients in China has reached 330 million, and this number may continue to increase with the intensification of aging. The "Digital Heart" product family, as an intelligent platform around the heart scene, the next 8 products have covered the whole disease cycle of health screening, in-hospital accurate diagnosis, preoperative accurate evaluation and out-of-hospital follow-up. At present, it has been commercially used in public hospitals, private hospitals, regional medical service centers and other medical institutions at all levels, serving tens of millions of people.

In July 2020, Digital Technology released the "digital brain" product family, focusing on 13 million stroke patients. In September 2020, a multicenter study was carried out by Jukun and Xuanwu Hospital, and the research results were published in a series of Nature journals. The research results show that: 1) AI performs well in improving hospital efficiency: from July to November 2019, the system was used in Xuanwu Hospital. The average post-processing time of the image was reduced from 14.22 ±3.64min to 4.94 ±0.36min, which was reduced by more than 3 times, and the number of clicks by technicians was reduced from 115.87 ±25.9to 4 times. After 5 months of use, the number of post-processing doctors was reduced from 3 to 1. 2) in the aspect of patient benefit, the traditional head and neck CTA examination obtains the vascular image by manual subtraction and bone removal, and the process is complicated, and the patient must undergo two scans, while the AI technique only requires the patient to complete one scan, which reduces the physical and mental pressure of the patient. At present, the product has been tested in more than 100 stroke centers across the country, showing very good clinical results.

The above series of products have been used in more than 400 third-class and first-class hospitals across the country, such as Peking Union Hospital, Beijing Anzhen Hospital, Shanghai Ruijin Hospital and so on. Among the top 30 cardiovascular hospitals of Fudan University, 29 hospitals have carried out in-depth clinical cooperation with Jukun in the cardiovascular field. In 2020, Jukun and strategic partner Philips Medical jointly created the heart intelligent CT solution, which greatly increased its market share and led the industry in commercialization.

Investor's point of view

Mr. Shen Nanpeng, global managing partner of Sequoia Capital, said: "Image diagnosis, as one of the most mature application scenarios for the combination of medical treatment and AI, ushered in the opening of three types of medical device certificates this year. This reflects the importance of AI to national medical innovation. Through differentiated clinical pathways, Jukun has achieved a breakthrough in technology and business model innovation in the field of heart and brain imaging. "

Mr. Zeng Zhiqiang, managing partner of Huagai Capital Medical Fund, said: "Huagai Capital has always been optimistic about the application prospect of artificial intelligence in the medical field. Starting from the "digital heart", Jukun has gradually built a series of AI products that meet the needs of clinical rigidity. At present, it has covered hundreds of hospitals and won the world's first class III certificate for medical imaging-assisted diagnosis of cardiac AI. "

Liu Qin, founding partner of Wuyuan Capital, said: "what impressed us most about General Mao and Anne at that time was the strategic path of differentiation. The company put the medical knowledge graph first and built the technological infrastructure of AI and cloud computing in a down-to-earth manner. Clear strategy and strong implementation guide the company to truly achieve AI empowerment to create medical value. What excites us even more is the evolution of the company from multiple vertical product matrices to an AI intelligent diagnostic infrastructure with more platform characteristics. It is expected that with the blessing of the new round of financing, Jukun will continue to contribute to the further balance between supply and demand and the improvement of efficiency of medical services. "

Zhou Wei, founding partner of founding partner CCV, said: "when investing in digital health care projects, we follow three logic. First of all, technology intervention can bring high-quality supply and achieve multiplier effect. Second, technical products are not only suitable for top hospitals in first-tier cities, but also can bring help to a large number of long-tail hospitals and clinics. Third, the product itself has a good large-scale commercialization ability. Jukun Technology chooses to do cardio-cerebrovascular imaging AI with a higher degree of difficulty. The differentiation of this business model makes it stand out in the homogenization competition. "

Yang Ruirong, partner of Yuanyi Capital, said: "as investors in the Angel Round, we are very happy to witness and accompany several Kuncong."Zero to oneThe course of development. Jukun's successful practice is a strong proof of digital technology to improve efficiency in the medical field and expand the boundaries of doctors' abilities. We hope that in the future, General Mao and Anne will be able to lead a team to bring value to more patients through digital technology, leading the industry and determining the future. "